anteo to be come household name in diagnostics

Anteo's unique product(s) have received significant attention from the big players in the medical/ diagnostics space. Very well renowned NASDAQ international and key Italian Diagnostic organisations are part of a wider group of companies (much larger) than Bangs which are on the verge of signing with Anteo.

As i understand it 2010 should yield up to 10-15 contracts similar to Bangs, with the expectation that ADO will become profitable and cashflow positive by year end. Currently ADO has circa 25 organisations trilling its Mix n Go product with resounding success.. Mix n Go provides significant efficiencies and cost savings to all Pathology/ Diagnostic Labs hence its appeal to the broader market and the large players (which i will not name) in particular. In brief its product is 500% more efficient than the product of its immediate competitors, while costing $0.82/Mg as opposed to $5.6/Mg charged by its competitor.

Conservatively speaking ADO's revenue streams could total $200-300m Per annum in the short term, providing fantastic upside to the share price - with only 500m shares listed on the market of which the majority is tightly held by its top 20.

Upcoming signings with some large diagnostic players are imminent.